Browsing Tag
Genmab
7 posts
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.
Why Merus is the hottest takeover target in oncology right now—Genmab said to be frontrunner
Genmab is reportedly close to acquiring Merus in a high-stakes biotech deal that could reshape the oncology sector. Read the full breakdown now.
AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing…
Genmab to acquire ProfoundBio in $1.8bn deal to enhance cancer treatment
In a landmark move within the biotechnology sector, Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have announced a…
Genmab, Pfizer’s tisotumab vedotin takes a leap towards EU approval for cervical cancer
In a significant development for cervical cancer treatment, Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) have…
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration…
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.